Actively Recruiting
Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms
Led by Swiss GO Trial Group · Updated on 2026-02-12
1000
Participants Needed
3
Research Sites
254 weeks
Total Duration
On this page
Sponsors
S
Swiss GO Trial Group
Lead Sponsor
U
University Hospital, Basel, Switzerland
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study/research is to assess the relationship between ultrasound features of the myometrium suggestive of adenomyosis and clinical symptoms of adenomyosis and to establish a reporting system for adenomyosis assessing disease severity. Consecutive pre- and perimenopausal symptomatic and asymptomicasymptomatic women with an uterus presenting for gynaecological ultrasound exams will be asked to participate in the study. Routine gynecologicalgynaecological ultrasound exams will be performed and study participants will fill out a questionnaire on their symptoms (if any) and bleeding pattern. There will be one visit and no interventions.
CONDITIONS
Official Title
Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women of pre- and perimenopausal age presenting for gynecologic ultrasound exam who provide voluntary informed written consent
- Both symptomatic and asymptomatic women
- Women using hormonal contraceptives or hormone replacement therapy (HRT) are eligible, with this information noted
You will not qualify if you...
- No written consent for the study
- Serious medical, psychiatric, or psychological conditions affecting decision-making ability
- Postmenopausal women
- Current pregnancy
- History of pelvic urogynaecologic surgery (e.g., TVT, mesh surgery)
- Malignancy or premalignancy of the uterus or cervix
- Prior myomectomy for FIGO 3-6 fibroids
- Coagulation disorders requiring anticoagulation medication
- History of diagnosed intraabdominal adhesions from surgery
- Prior diagnosis of pelvic congestion syndrome
- Psychiatric disease preventing reliable pain assessment
- Prior surgery or treatment for deep infiltrating endometriosis
- Acute urinary symptoms such as dysuria, urgency, or severe stress incontinence
- Acute or chronic pelvic infection (e.g., cervicitis, endometritis, salpingitis)
- Presence of ovarian lesions
- Sonographic signs of deep infiltrating endometriosis (DIE)
- Intracavitary pathology including fibroids (FIGO 0-2), polyps, or adhesions
- Retained products of conception
- Presence of any fibroid larger than 2 cm in diameter
- More than 3 small fibroids under 2 cm are allowed and not exclusionary
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Medical University of Silesia
Sosnowiec, Poland, 41-200
Actively Recruiting
2
Hospital Universitari Dexeus
Barcelona, Spain, 08028
Actively Recruiting
3
University Hospital Basel
Basel, Canton of Basel-City, Switzerland, 4031
Actively Recruiting
Research Team
G
Gwendolin Manegold-Brauer, Prof. Dr.
CONTACT
T
Team Swiss GO Trial Group, +41613284203
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here